Member access

4-Traders Homepage  >  Shares  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

0
Real-time Quote. Real-time Tradegate - 03/04 04:02:03 pm
68.215 EUR   -2.05%
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (cert..
01/07 UCB : Acquisition of own shares
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Deutsche Boerse Ag
02/26/2015 02/27/2015 03/02/2015 03/03/2015 03/04/2015 Date
68.368(c) 69.36(c) 68.44(c) 69.64(c) 67.75 Last
0 0 167 22 50 Volume
+1.30% +1.45% -1.33% +1.75% -2.71% Change
More quotes
Company
UCB SA is a biopharmaceutical company that engages in the research, development and commercialization of innovative drugs in the fields of central nervous system and immunology disorders.It focuses on the discovery and development of innovative medicines and solutions to transform the lives of... 
Sector
Pharmaceuticals
Calendar
04/23Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 347 M
EBIT 2014 435 M
Net income 2014 233 M
Debt 2014 1 561 M
Yield 2014 1,57%
Sales 2015 3 631 M
EBIT 2015 554 M
Net income 2015 325 M
Debt 2015 1 392 M
Yield 2015 1,74%
PER 2014 52,91
PER 2015 38,51
EV / Sales 2014 4,38x
EV / Sales 2015 3,99x
Capitalization 13 108 M
More Financials
Latest news on UCB SA
02/12 UCB : Patent Issued for Systems for Administering Medication
02/12 UCB : Patent Issued for Syringe Safety Assembly
01/28 UCB : announces US and EU regulatory filings for the investigational antiepilept..
01/12 UCB : Update of transparency notification UCB SA/NV
01/09 DERMIRA : and UCB announce start of Phase 3 program for CIMZIA (certolizumab peg..
01/07 UCB : Acquisition of own shares
2014 UCB : Selects Cegedim Relationship Management Mobile Intelligence Cloud Platform
2014 UCB : "Method for Producing Protein" in Patent Application Approval Process
More news
Sector news Biopharmaceuticals
05:46p ACTAVIS : Confirms District Court Ruling In Atelvia® Patent Litigation
04:48p AMGEN : Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis..
04:48p AMGEN : Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowerin..
Plus d'actualités du secteur Biopharmaceuticals
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF